IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Ranbaxy Drops Out of Battle for Merck KGaA’s Generics Unit

11:34 AM MDT | July 27, 2007 | Deepti Ramesh

The largest pharma company in India, Ranbaxy Laboratories (Gurgaon) has dropped out of the second round of bidding for German pharma major, Merck KGaA’s generics business unit, according to a series of unconfirmed media reports at CW press time last week. The other companies believed to still be in the race for the generic unit are Teva Pharmaceuticals (Petach Tikva, Israel), Actavis (Reykjavik, Iceland), and Mylan Laboratories (Pittsburgh). The estimated worth of Merck’s generics business is around $6 billion, industry sources say. Ranbaxy declined...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa